The first enterprise in China to obtain the license for producing pentavalent vaccines

Newcastle Disease, Infectious Bronchitis, Avian Influenza and Infectious Bursal Disease Vaccine, Inactivated

Indication / Application:For the prevention of Newcastle Disease, Infectious Bronchitis, Avian Influenza (H9 subtype) and Infectious Bursal Disease.
Manufacturing: Produced in GMP-certified facility
Supply Mode: Bulk Supply / Distributor / OEM Available
Origin: China

Generic Name

Newcastle Disease, Infectious Bronchitis, Avian Influenza and Infectious Bursal Disease Vaccine, Inactivated

Composition and Content

Disease	Antigen	Antigen Content	Optional Strain(s)
ND	La Sota	≥ 10^8.5 EID₅₀/0.1ml	G7; La Sota+G7
IB	M41	≥ 10^6.5 EID₅₀/0.1ml	QX; M41+QX
AI(H9N2)	Clade 9.4.2.5	≥ 10^8.5 EID₅₀/0.1ml	H9(9.4.1a); H9(9.4.1b)
IBD	rVP2: (nVarIBDV+nvvIBDV)	Each ≥ 6.34 μg/0.1ml	-

Indications

For the prevention of Newcastle Disease, Infectious Bronchitis, Avian Influenza (H9 subtype) and Infectious Bursal Disease. Immunity is generated 14–21 days after immunization, the duration of immunity is 3 months for young chickens and 6 months for adult chickens

Dosage and Administration

Administer subcutaneously in the neck or intramuscularly: 0.3 ml per bird for chickens under 3 weeks of age; 0.5 ml per bird for chickens over 3 weeks of age.

Adverse Reactions

Generally, no adverse reactions occur.

Specification

250 ml/bottlen, 40 bottles/carton; 500 ml/bottle, 20 bottles/carton.

Storage and Shelf Life

Store at 2-8°C; Valid for 24 months.

Appearance

A uniform milky-white emulsion.

Precautions

1. Vaccinate healthy chickens only. Do not use in emaciated or sick chickens.
2. Before use, check for a damaged vial, missing label, foreign matter, or severe oil-water separation. Do not use if any abnormality is found.
3. Allow the vaccine to reach room temperature and shake thoroughly before use.
4. Use within 2 hours after first opening and prevent contamination.
5. This vaccine may be used with live Newcastle disease and infectious bronchitis vaccines to enhance cellular and mucosal immunity.

Features

After a decade of R&D, WollVac’s latest product makes its grand launch in 2025. Offering "one injection for five protections," it enhances epidemic prevention efficiency and effectiveness.
Featuring carefully selected strains and viral composite subunit antigens, this innovative solution is a pioneering breakthrough in China. Formulated with a composite adjuvant, it leverages the advantages of compound vegetable oil to ensure zero stress on animals.

The use of complex antigens:

Serotype matching is essential for effective vaccine protection. Using real-time data from the Shandong Provincial Engineering Laboratory for Animal Pathogenic Microorganisms Testing Center, the R&D Center evaluates prevalent strains from the epidemic pathogen bank through multiple stages—preliminary lab screening, animal testing, and cross-protective antibody assessment. The selected dominant strains ensure broad and high-efficacy protection.

Antigen	ND	IB	AI H9N2	FADV	IBDV
Strain	VII type	QX	h 9.4.1.a + h 9.4.1.b h 9.4.2.5b + h 9.4.2.5c	C4 + E8b + D11	cvvIBDV + nvIBDV